EE200100366A - Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks - Google Patents

Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks

Info

Publication number
EE200100366A
EE200100366A EEP200100366A EEP200100366A EE200100366A EE 200100366 A EE200100366 A EE 200100366A EE P200100366 A EEP200100366 A EE P200100366A EE P200100366 A EEP200100366 A EE P200100366A EE 200100366 A EE200100366 A EE 200100366A
Authority
EE
Estonia
Prior art keywords
cancer
antibodies
preparation
pharmaceutical composition
prophylactically
Prior art date
Application number
EEP200100366A
Other languages
English (en)
Inventor
Eckert Helmut
Loibner Hans
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag filed Critical Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag
Publication of EE200100366A publication Critical patent/EE200100366A/et
Publication of EE05474B1 publication Critical patent/EE05474B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200100366A 1999-01-13 2000-01-12 Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks EE05474B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH5199 1999-01-13
PCT/EP2000/000174 WO2000041722A1 (de) 1999-01-13 2000-01-12 Verwendung von antikörpern zur vakzinierung gegen krebs

Publications (2)

Publication Number Publication Date
EE200100366A true EE200100366A (et) 2002-10-15
EE05474B1 EE05474B1 (et) 2011-10-17

Family

ID=4178206

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100366A EE05474B1 (et) 1999-01-13 2000-01-12 Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud v„hivastaseks vaktsineerimiseks

Country Status (28)

Country Link
US (3) US7691372B2 (et)
EP (2) EP1140168B1 (et)
JP (1) JP4774551B2 (et)
KR (1) KR100771752B1 (et)
CN (1) CN1188169C (et)
AT (2) ATE286745T1 (et)
AU (1) AU768515B2 (et)
CA (1) CA2360382C (et)
CZ (1) CZ302801B6 (et)
DE (2) DE50000243D1 (et)
DK (2) DK1140168T3 (et)
EE (1) EE05474B1 (et)
ES (2) ES2236375T3 (et)
HK (1) HK1044487B (et)
HR (1) HRP20010526A2 (et)
HU (1) HU226150B1 (et)
ID (1) ID30223A (et)
IL (2) IL144265A0 (et)
IS (1) IS5998A (et)
MX (1) MXPA01007148A (et)
NO (1) NO329917B1 (et)
NZ (1) NZ512722A (et)
PL (1) PL201533B1 (et)
PT (2) PT1230932E (et)
SI (2) SI1230932T1 (et)
SK (1) SK286627B6 (et)
TR (1) TR200102034T2 (et)
WO (1) WO2000041722A1 (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1044487B (zh) * 1999-01-13 2005-09-16 伊格尼昂癌症治疗研发股份公司 抗体用於抗癌接种的用途
AT410172B (de) 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500647A1 (de) * 2002-05-21 2006-02-15 Igeneon Krebs Immuntherapie Verwendung eines impfstoffes
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2006005367A1 (en) 2004-07-14 2006-01-19 Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag N-glycosylated antibody
ATE483473T1 (de) * 2004-07-20 2010-10-15 Altropus Gmbh Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
US7976852B2 (en) * 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
US9119414B2 (en) 2007-12-07 2015-09-01 N.V. Nutricia Bifidobacterium for dust mite allergy
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8887373B2 (en) 2012-02-24 2014-11-18 Covidien Lp Vessel sealing instrument with reduced thermal spread and method of manufacture therefor
US20140276968A1 (en) * 2013-03-14 2014-09-18 Ethicon, Inc. Applicator systems for surgical fasteners
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) * 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1997005597A1 (en) * 1995-07-31 1997-02-13 Litton Systems Canada Limited Flat panel pixel array incorporating photoconductive switches
WO1997015597A1 (en) * 1995-10-25 1997-05-01 Centocor B.V. HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
IL121041A0 (en) * 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
US6274143B1 (en) * 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
HK1044487B (zh) * 1999-01-13 2005-09-16 伊格尼昂癌症治疗研发股份公司 抗体用於抗癌接种的用途
WO2001087233A2 (en) 2000-05-16 2001-11-22 New York University Anti-idiotypic antibody against fimh adhesin of uropathogenic type i-fimbriated escherichia coli, compositions and method of use thereof

Also Published As

Publication number Publication date
MXPA01007148A (es) 2002-03-27
EP1230932A2 (de) 2002-08-14
US20100233178A1 (en) 2010-09-16
DE50000243D1 (de) 2002-08-01
HK1044487A1 (en) 2002-10-25
US8444974B2 (en) 2013-05-21
EP1140168A1 (de) 2001-10-10
ATE286745T1 (de) 2005-01-15
US7691372B2 (en) 2010-04-06
AU768515B2 (en) 2003-12-18
SK9642001A3 (en) 2002-03-05
EP1230932B1 (de) 2005-01-12
PT1230932E (pt) 2005-04-29
CA2360382C (en) 2011-05-24
DK1230932T3 (da) 2005-04-25
NO20013093D0 (no) 2001-06-21
CN1188169C (zh) 2005-02-09
EP1230932A3 (de) 2003-11-26
PT1140168E (pt) 2002-11-29
KR100771752B1 (ko) 2007-10-30
WO2000041722A1 (de) 2000-07-20
CN1344167A (zh) 2002-04-10
CZ20012581A3 (cs) 2002-01-16
SK286627B6 (sk) 2009-02-05
NO20013093L (no) 2001-09-10
HUP0200527A2 (en) 2002-06-29
NZ512722A (en) 2003-07-25
IS5998A (is) 2001-07-10
US20070224202A1 (en) 2007-09-27
HU226150B1 (en) 2008-05-28
DE50009240D1 (de) 2005-02-17
ES2177509T3 (es) 2002-12-16
ID30223A (id) 2001-11-15
CA2360382A1 (en) 2000-07-20
ES2236375T3 (es) 2005-07-16
HRP20010526A2 (en) 2002-08-31
JP4774551B2 (ja) 2011-09-14
IL144265A (en) 2006-08-20
CZ302801B6 (cs) 2011-11-16
IL144265A0 (en) 2002-05-23
PL201533B1 (pl) 2009-04-30
HK1044487B (zh) 2005-09-16
EP1140168B1 (de) 2002-06-26
AU2796400A (en) 2000-08-01
DK1140168T3 (da) 2002-09-30
EE05474B1 (et) 2011-10-17
SI1230932T1 (en) 2005-06-30
KR20010101446A (ko) 2001-11-14
TR200102034T2 (tr) 2001-11-21
PL364747A1 (en) 2004-12-13
US20120003232A1 (en) 2012-01-05
SI1140168T1 (en) 2002-10-31
JP2002534481A (ja) 2002-10-15
NO329917B1 (no) 2011-01-24
ATE219687T1 (de) 2002-07-15

Similar Documents

Publication Publication Date Title
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks
EE05212B1 (et) Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i
EA200500441A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
DE60134962D1 (de) Anti-ccr4 antikörper und fragmente davon
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
DK1383785T3 (da) Rekombinant tumorspecifikt antistof og anvendelse deraf
FI1897548T4 (fi) T-solujen säätely
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
TR200001253T2 (tr) Tümöre özel antijenler
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
ATE483473T1 (de) Verwendung von antikörpern in einer sehr geringen dosis zur impfung gegen krebs
BR0007814A (pt) Uso de anticorpos para a vacinação contra câncer
BR9815993A (pt) Comprimido de liberação cronometrada compreendendo naproxen e pseudoefedrina

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20130112